Efficacy of a trivalent influenza vaccine against seasonal strains and against 2009 pandemic H1N1: A randomized, placebo-controlled trial

William J.H. McBride a,⇑, Walter P. Abhayaratna b,c, Ian Barr d, Robert Booy e, Jonathan Carapetis f, Simon Carson g, Ferdinandus De Looze h, Rod Ellis-Pegler i, Leon Heron c, Jeff Karrasch j, Helen Marshall k, Jodie Mcvernon l,1, Terry Nolan l, William Rawlinson m, Jim Reid n, Peter Richmond o, Sepehr Shakib p, Russell L. Basser q, Gunter F. Hartel q,2, Michael H. Lai q,3, Steven Rockman q, Michael E. Greenberg q,4

a James Cook University, Cairns Hospital Clinical School, Cairns, Queensland 4870, Australia
b ANU College of Medicine, Biology and Environment, Australian National University, Canberra, Australian Capital Territory 2601, Australia
c World Health Organization Collaborating Centre for Reference and Research on Influenza, North Melbourne, Victoria 3051, Australia
d National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The University of Sydney and The Children's Hospital at Westmead, New South Wales 2145, Australia
e Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory 0810, Australia
f Southern Clinical Trials Ltd, Christchurch 8013, New Zealand
g Trialworks Clinical Research Pty Ltd and Discipline of General Practice, School of Medicine, University of Queensland, Brisbane, Queensland 4067, Australia
h Auckland Clinical Studies, Auckland 1072, New Zealand
i Redcliffe Hospital, Redcliffe, Queensland 4020, Australia
j Vaccinology and Immunology Research Trials Unit (VIRTU), Women's and Children's Hospital, Robinson Research Institute and School of Medicine, University of Adelaide, Adelaide, South Australia 5006, Australia
k Vaccine and Immunization Research Group, Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, Victoria 3052, Australia
l South Eastern Sydney and Illawarra Area Health Service and University of New South Wales, Sydney, New South Wales 2052, Australia
m Dunedin School of Medicine, University of Otago, Dunedin 9054, New Zealand
n University of Western Australia, School of Paediatrics and Child Health, Princess Margaret Hospital for Children, Perth, Western Australia 6872, Australia
o Discipline of Pharmacology, School of Medical Sciences, University of Adelaide, Adelaide, South Australia 5001, Australia
p Clinical Research and Development, CSL Limited, Parkville, Victoria 3052, Australia

A R T I C L E   I N F O

Article history:
Received 4 April 2016
Received in revised form 31 July 2016
Accepted 11 August 2016
Available online 29 August 2016

Keywords:
Cross-protection
Influenza A virus
H1N1 subtype
Influenza vaccine efficacy

A B S T R A C T

Background: Before pandemic H1N1 vaccines were available, the potential benefit of existing seasonal trivalent inactivated influenza vaccines (IIV3s) against influenza due to the 2009 pandemic H1N1 influenza strain was investigated, with conflicting results. This study assessed the efficacy of seasonal IIV3s against influenza due to 2008 and 2009 seasonal influenza strains and against the 2009 pandemic H1N1 strain.

Methods: This observer-blind, randomized, placebo-controlled study enrolled adults aged 18–64 years during 2008 and 2009 in Australia and New Zealand. Participants were randomized 2:1 to receive IIV3 or placebo. The primary objective was to demonstrate the efficacy of IIV3 against laboratory-confirmed influenza. Participants reporting an influenza-like illness during the period from 14 days after vaccination until 30 November of each study year were tested for influenza by real-time reverse transcription

⇑ Corresponding author at: College of Medicine and Dentistry, James Cook University, Cairns Clinical School, Cairns Hospital, PO Box 902, Cairns, Queensland 4870, Australia.
E-mail addresses: john.mcbride@jcu.edu.au (W.J.H. McBride), walter.abbayaratna@act.gov.au (W.P. Abhayaratna), Ian.Barr@fluCentre.org (I. Barr), Robert.booy@health.nsw.gov.au (R. Booy), jonathan.carapetis@telethonkids.org.au (J. Carapetis), Simon.Carson@csiro.au (S. Carson), freddeelooze@ausstralis.com.au (F. De Looze), rodlep@gmail.com (R. Ellis-Pegler), LeonH@chw.edu.au (L. Heron), jeffkarrasch@gmail.com (J. Karrasch), helen.marshall@adelaide.edu.au (H. Marshall), j.mcvernon@unimelb.edu.au (J. Mcvernon), t.nolan@unimelb.edu.au (T. Nolan), w.rawlinson@unsw.edu.au (W. Rawlinson), jim.reid@otago.ac.nz (J. Reid), ssshakib@gmail.com (S. Shakib), Russell.Basser@securis.com (R.L. Basser), GunterF.Hartel@novartis.com (G.F. Hartel), michael_h_lai@novartis.com (M.H. Lai), Steve.Rockman@seqirus.com (S. Rockman), Michael.greenberg@sanofipasteur.com (M.E. Greenberg).

1 Present address: Modelling and Simulation Unit, Melbourne School of Population and Global Health, The University of Melbourne, Victoria 3010, Australia and Murdoch Childrens Research Institute, Parkville, Victoria 3052, Australia.
2 Present address: Hartel Consulting, Brisbane, Queensland 4170, Australia.
3 Present address: Novartis Pharma AG, Retina Development Franchise, Novartis Campus, 4056 Basel, Switzerland.
4 Present address: Sandhi Pasteur, San Francisco, CA 94107, USA.

http://dx.doi.org/10.1016/j.vaccine.2016.08.038
©2016 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
polymerase chain reaction.

Results: Over a study period of 2 years, 15,044 participants were enrolled (mean age ± standard deviation: 35.5 ± 14.7 years; 54.4% female). Vaccine efficacy of the 2008 and 2009 IIV3s against influenza due to any strain was 42% (95% confidence interval [CI]: 30%, 52%), whereas vaccine efficacy against influenza due to the vaccine-matched strains was 60% (95% CI: 44%, 72%). Vaccine efficacy of the 2009 IIV3 against influenza due to the 2009 pandemic H1N1 strain was 38% (95% CI: 19%, 53%). No vaccine-related deaths or serious adverse events were reported. Solicited local and systemic adverse events were more frequent in IIV3 recipients than placebo recipients (local: IIV3 74.6% vs placebo 20.4%, p < 0.001; systemic: IIV3 46.6% vs placebo 39.1%, p < 0.001).

Conclusions: The 2008 and 2009 IIV3s were efficacious against influenza due to seasonal influenza strains and the 2009 IIV3 demonstrated moderate efficacy against influenza due to the 2009 pandemic H1N1 strain.

Funded by CSL Limited, ClinicalTrials.gov identifier NCT00562484
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
2.4. Safety assessments

Solicited adverse events (AEs) and oral temperature were recorded in diary cards on the evening of vaccination and every evening for the next 4 days. Unsolicited AEs that occurred on the day of vaccination and for the 20 days after were recorded in diary cards. Information regarding the occurrence of serious adverse events (SAEs) was collected from the day of vaccination to 180 days after study vaccination. A data monitoring committee was established according to United States Food and Drug Administration guidelines [23].

2.5. Clinical and laboratory outcomes

Stimulated by weekly reminder contacts from investigators, participants reported signs and symptoms of an influenza-like illness (ILI) from day 14 after vaccination until 30 November of the respective study year, the time typically marking the end of influenza circulation in the Southern Hemisphere. An ILI was defined as at least one respiratory symptom (e.g., cough, sore throat, nasal congestion) and at least one systemic symptom (e.g., fever ≥37.8 °C [oral], feverishness, chills, body aches). This broad case definition was chosen to maximize the chance of detecting influenza infections. Participants who reported signs and symptoms of an ILI had nose and throat swab specimens collected within 72 h of symptom onset for laboratory confirmation of influenza infection. Laboratory-confirmed influenza was defined as a nose or throat specimen testing positive by viral culture and/or real-time reverse transcription polymerase chain reaction (rtRT-PCR, Focus Diagnostics, Cypress, CA, USA). Laboratory-confirmed cases were typed to determine whether they matched the strains included in the vaccine. Except for those specimens identified to be 2009 H1N1 by rtRT-PCR, influenza strain typing was determined by gene sequencing (for A subtypes H1N1 and H3N2) or pyrosequencing (for B strains) performed by the WHO Collaborating Centre (Melbourne, Australia) [24].

2.6. Statistical analysis

Vaccine efficacy was assessed for each influenza virus type and subtype only for laboratory-confirmed cases that occurred 14 or more days after vaccination and before 30 November of each trial year. Vaccine efficacy was defined as the relative reduction in influenza rate in the IIV3 group relative to the placebo group, i.e., vaccine efficacy = 1 – (IIV3 recipient infection rate/placebo recipient infection rate). The primary analysis tested whether vaccine efficacy versus placebo was significantly greater than or equal to 40%. The primary endpoint was achieved if the lower bound of the (1 – 2x) × 100% confidence interval (CI) for vaccine efficacy was 40% or higher.

The study was designed as a 2-year study with an interim analysis after the first season. A Pocock alpha-spending function was used to maintain an overall one-sided α = 0.025 for the primary endpoint, whereby in the first season α = 0.01550 and in the second season α = 0.01387. Assuming an influenza attack rate of at least 3% and a vaccine efficacy of at least 70%, then a first season sample size of N = 7500 randomized participants in a 2:1 ratio to least 3% and a vaccine efficacy of at least 70%, then a first season used to maintain an overall one-sided analysis after the first season. A Pocock alpha-spending function was established according to United States Food and Drug Administration guidelines [23].

The primary analysis assessed vaccine efficacy against any influenza infection and infections caused by vaccine-matched strains. A post hoc analysis of efficacy against non-vaccine strains was also carried out to assess cross-protection. In addition, for the 2009 season, where most cases were of the pandemic H1N1 strain, vaccine efficacy was also analyzed by age strata (17–39 years, 40–54 years, and 55–65 years).

3. Results

3.1. Demographic and baseline clinical characteristics

The first year of the study was conducted between 25 February 2008 and 28 January 2009, and the second year between 9 March 2009 and 29 January 2010. A total of 15,479 individuals were assessed for eligibility, and 15,044 were randomly assigned to a study arm (7544 in 2008, 7500 in 2009, Fig. 1). The mean age of participants was 35.5 years and 9.6% reported having received a seasonal influenza vaccine during the 12 months before entering the study (Table 1). Approximately 90% of participants were White and approximately 55% were female. Most (63%) had never previously received an influenza vaccination, and most were non-smokers.

Protocol violations occurred in 41 (0.3%) participants and were distributed equally between study arms (IIV3 group: 28 [0.3%] participants; placebo group: 13 [0.3%] participants). Note that 2 participants aged 17 years and 2 participants aged 65 years were enrolled in the study and included in the evaluable population.

3.2. Concomitant medications

A total of 7194 (47.9%) participants were receiving concomitant medications at baseline. The most frequently recorded baseline medications were birth control medications (ethinylestradiol/levonorgestrel: 1122 [7.5%] participants; ethinylestradiol/cyproterone acetate; 419 [2.8%] participants) and salbutamol (375 [2.5%] participants), taken by similar proportions of participants in the IIV3 and placebo groups.

Influenza vaccines other than the study vaccine were received by 140 (0.9%) participants during on-study periods (IIV3 group: 108 [1.1%] participants; placebo group: 32 [0.6%] participants). Of these, 135 participants reported receiving the 2009 H1N1 pandemic influenza vaccine (Table 1). All 140 participants were excluded from the efficacy analysis before unblinding. An additional 40 participants who took other prohibited medications (e.g., immunosuppressive therapy) were excluded from the efficacy analysis before unblinding.

3.3. Vaccine efficacy

In the 2008 and 2009 influenza seasons combined, laboratory-confirmed influenza was identified in 222 of 9889 (2.2%) IIV3 recipients and 192 of 4960 (3.9%) placebo recipients (Table 2). The incidence of laboratory-confirmed influenza during the 12 months before entering the study (Table 1). Approximately 90% of participants were White and approximately 55% were female. Most (63%) had never previously received an influenza vaccination, and most were non-smokers.

Protocol violations occurred in 41 (0.3%) participants and were distributed equally between study arms (IIV3 group: 28 [0.3%] participants; placebo group: 13 [0.3%] participants). Note that 2 participants aged 17 years and 2 participants aged 65 years were enrolled in the study and included in the evaluable population.
post hoc analysis of vaccine efficacy against influenza strains not included in the vaccine yielded variable results. Vaccine efficacy against mismatched B strains (9.7%; 95% CI: 85.8%, 35.2%) and against mismatched H3N2 (49.8%; 95% CI: 73.2%, 85.5%) was not statistically significant (Table 2, Fig. 2). By contrast, vaccine efficacy against the 2009 pandemic H1N1 strain was 38.3% (95% CI: 19.3%, 52.8%; Table 2, Fig. 2).

Post hoc analysis by age suggested that the efficacy of the 2009 IIV3 against the 2009 pandemic H1N1 strain was highest in older participants compared with younger participants. In participants 55–65 years of age, vaccine efficacy against the 2009 pandemic strain was 65.8% (95% CI: 46.3%, 87.7%), whereas in participants 17–39 years of age, vaccine efficacy was 38.1% (95% CI: 16.1%, 54.4%). Vaccine efficacy in participants 40–54 years of age was 21.6%; however, the CIs were wide and included 0 (95% CI: −56.3%, 60.7%). However, the differences in vaccine efficacy between age groups were not statistically significant for the 2009 pandemic H1N1 strain (logistic regression analysis, p = 0.416).

In contrast, post hoc analysis by age suggested similar vaccine efficacy against matched strains across 2008 and 2009 between age groups. In participants 55–65 years of age, vaccine efficacy against all matched strains was 68.4% (95% CI: 3.7%, 89.6%), whereas in participants 17–39 years of age, vaccine efficacy was 55.1% (95% CI: 30.3%, 71.1%). Vaccine efficacy in participants 40–54 years of age was 66.7% (95% CI: 37.2%, 82.3%). The differences in vaccine efficacy between age groups were not statistically significant for the matched strains (logistic regression analysis, p = 0.683).

### 3.4. Adverse events

No vaccine-related deaths or SAEs were reported. One or more solicited local AEs were reported by 74.6% of IIV3 recipients and by 20.4% of placebo recipients (p < 0.001; Fig. 2A). Pain and injection-site tenderness were the most frequently reported local events. Solicited systemic AEs were less common than local events, with one or more AEs reported by 46.6% of IIV3 recipients and 39.1% of placebo recipients (p < 0.001; Fig. 2B). Malaise, headache, and myalgia were the most frequently reported systemic AEs in both groups. The majority of solicited local and systemic AEs were of mild to moderate intensity and of limited duration (less than 3 days). The frequency of unsolicited AEs was similar between treatment groups (IIV3 group: 33.9%; placebo group: 35.1%).

### 4. Discussion

Despite being conducted during two influenza seasons with substantial mismatch between vaccine and circulating influenza strains (in 2008, influenza B was the predominant circulating type whereas in 2009, pandemic A(H1N1)pdm09 was predominant [25]), this large, randomized, placebo-controlled trial...
demonstrated efficacy against influenza due to vaccine-matched influenza strains. Efficacy was also demonstrated for a seasonal influenza vaccine against influenza due to laboratory-confirmed 2009 H1N1 infection.

A possible explanation for the observed cross-protection of the 2009 IIV3 against the 2009 pandemic H1N1 strain is the stimulation of cross-reactive antibodies. Cross-reactive antibodies may be vaccine strain-specific or boosting of antibodies directed at earlier influenza strains to which the individual was exposed. We observed a boosting of cross-reactive antibodies in our clinical trials of monovalent 2009 H1N1 vaccine in adults and children in Australia [26,27], where individuals who had previously received 2009 IIV3 had higher pre-vaccination antibody titers to 2009 H1N1 than those who had not received the vaccine. The findings of the current study are supported by data from other studies of antibody cross-reactivity in individuals before and after receipt of IIV3 [28], although in those studies the effect was greater for those aged over 60 years [4,29]; the magnitude of efficacy was highest in those over 55 years in our study. This further suggests that protective efficacy may be a result of cross-protective immunity from multiple vaccinations or exposure to a related virus earlier in life, i.e., some degree of original antigenic sin. Induction of cross-reactive T cell responses to conserved viral epitopes may also be a factor underlying the cross-protection observed in this study [30].

Table 2
Laboratory-confirmed influenza cases, attack rates, and vaccine efficacy (overall, against vaccine-matched strains, and against non-vaccine strains).

<table>
<thead>
<tr>
<th>Study year/influenza infections</th>
<th>Placebo</th>
<th>IIV3</th>
<th>Vaccine efficacy % (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cases n</td>
<td>Attack rate %</td>
<td>Cases n</td>
</tr>
<tr>
<td>2008/2009 combined</td>
<td>n = 4960</td>
<td>3.9</td>
<td>n = 9889</td>
</tr>
<tr>
<td>All</td>
<td>192</td>
<td>1.5</td>
<td>222</td>
</tr>
<tr>
<td>Vaccine-matched</td>
<td>73</td>
<td>3.3</td>
<td>97</td>
</tr>
<tr>
<td>2008</td>
<td>n = 2501</td>
<td>2.5</td>
<td>n = 5014</td>
</tr>
<tr>
<td>All</td>
<td>62</td>
<td>0.8</td>
<td>53</td>
</tr>
<tr>
<td>Vaccine-matched</td>
<td>20</td>
<td>0.3</td>
<td>44</td>
</tr>
<tr>
<td>B</td>
<td>110</td>
<td>4.5</td>
<td>125</td>
</tr>
<tr>
<td>2009</td>
<td>n = 2459</td>
<td>0.5</td>
<td>n = 4875</td>
</tr>
<tr>
<td>All</td>
<td>11</td>
<td>0.2</td>
<td>5</td>
</tr>
<tr>
<td>Vaccine-matched</td>
<td>5</td>
<td>0.1</td>
<td>5</td>
</tr>
<tr>
<td>H1N1a (pandemic)</td>
<td>94</td>
<td>3.8</td>
<td>115</td>
</tr>
</tbody>
</table>

Abbreviations: CI = confidence interval; IIV3 = inactivated influenza vaccine trivalent.

* All H1N1 infections in 2009 were identified as pandemic H1N1.

Fig. 2. Solicited adverse events within 5 days of vaccination. Panel A: Local adverse events; Panel B: Systemic adverse events; *p < 0.05 versus placebo.
This randomized controlled study demonstrated protection by seasonal IIV3 against laboratory-confirmed 2009 H1N1 influenza in adults. Two other randomized controlled studies that have investigated the efficacy of seasonal IIV3s against the 2009 pandemic H1N1 strain were conducted in children in Hong Kong [31,32]. The first small pilot study (N = 119) conducted during 2009 found no evidence of protection (or harm), but was not powered to investigate this outcome [30]. The second larger study (N = 796) conducted in 2009–2010 showed children who received IIV3 had a reduced risk of pandemic influenza A, with a vaccine efficacy estimate of 47% (95% CI, 15–67%) [32].

The 2008 and 2009 IIV3s were generally well tolerated, with no safety concerns identified. It should be noted that the subsequent 2010 IIV3 was associated with an unexpected increase in postmarketing reports of febrile seizure compared with previous seasonal IIV3s, predominantly in children <5 years of age. This was likely due to the combination of the new influenza strains included in the 2010 IIV3 and the CSL standard method of manufacture. This method preserved strain-specific viral components of the new influenza strains, heightening immune activation of innate immune cells, which, in a small proportion of children <5 years of age, was associated with the occurrence of febrile seizures [33,34]. No patient in the current study reported febrile seizures during the study period.

The strengths of this study were the randomized, placebo-controlled design, relatively large size, and use of a clinical efficacy endpoint rather than a serological surrogate endpoint. As such, the study was less subject to the potential sources of bias and confounding associated with the previously reported observational studies. Nevertheless, this study is subject to certain limitations. There was no description of the clinical course of influenza infection among vaccinated and unvaccinated cases, so we cannot report the impact of vaccination on the course of illness or associated co-morbidity. Our study population was limited to healthy adults 17–65 years of age (mean, 35 years), so we cannot address the impact of seasonal IIV3 on preventing 2009 H1N1 in children, a group more immunologically naïve to influenza. Most subjects were also female, non-smokers, influenza-vaccine naïve, white, and not Hispanic. In addition, our study did not measure serologic endpoints for influenza infection and, therefore, we can report efficacy only against symptomatic influenza infection.

The formulations for the 2009 Southern Hemisphere and 2009/10 Northern Hemisphere contained identical influenza A strains. As the monovalent H1N1 vaccine was not available during the first wave of the 2009 influenza pandemic, this study suggests that any use of seasonal vaccine in either the Southern or Northern Hemisphere may have had a positive impact on mitigating the peak incidence of pandemic H1N1 infections. Pre-pandemic mathematical modelling indicated that a vaccine, even one with low efficacy, used early in a pandemic could have meaningful benefit in reducing the amplitude of the pandemic wave [35].

5. Conclusions

The 2008 and 2009 seasonal IIV3s demonstrated clinical efficacy in healthy adults against influenza infection caused by the strains included in the vaccines. In addition, the 2009 seasonal IIV3 conferred significant clinical efficacy in healthy adults against laboratory-confirmed 2009 pandemic H1N1 infection.

Funding support

This study was sponsored by CSL Limited, manufacturer of Fluvax®. Editorial assistance was provided by Justine Southby, PhD, CMPP, and Luke Carey, PhD, of ProScribe – Envision Pharma Group, and was funded by CSL Limited. ProScribe’s services complied with international guidelines for Good Publication Practice (GPP3).

Role of the sponsor

The study sponsor was responsible for the final study protocol, oversaw the data management and analysis, and was involved in the interpretation of the data, the writing of the manuscript, and the decision to submit the manuscript for publication.

Role of contributors

PR, RB, LH, JK, TN, RLB, and GFH designed the study. IB was responsible for strain typing. PR, WPA, RB, SC, FDL, RE-P, LH, JK, HM, WJHM, JM, TN, WR, JR, and SS recruited subjects into the study. GFH was responsible for data analysis. All authors contributed to writing of the report. All authors saw and approved the final version of the report.

Conflict of interest

RLB, GFH, MHL, SR, and MEG are/were employees of CSL and hold shares. PR has received research funding and travel support for investigator meetings from CSL. IB has received grant funding from CSL under contract for influenza virus identification. RB has received funding from CSL, Roche, Sanofi Pasteur, GSK and Pfizer to conduct research or attend and present at scientific meetings. Any funding received is directed to a research account at The Children’s Hospital at Westmead and is not personally accepted by RB. FDL has received support from Trialworks Clinical Research Services to attend investigator meetings. RE-P has received funding for clinical trial participation and trial-related travel from Auckland Clinical Studies and paid to his institution. LH has received research funding from CSL, Novartis, Sanofi-Aventis, Roche, and GSK, paid to his institution. JK has received funding from CSL for clinical trial recruitment and travel to investigator meetings. HM has received travel support from CSL and Novartis Vaccines to present independent scientific data and research grants paid to her institution from CSL, Novartis Vaccines, and Pfizer Vaccines. WJHM has received travel support for investigator meetings from CSL but no direct funds and holds shares in CSL. JM has received research funding and travel support for investigator meetings from CSL, has served as a consultant and speaker for Novartis, and as a consultant for the governments of Australia and Mongolia. All support has been paid directly to her institution. TN’s institution (MCRI) has received research support from CSL, Sanofi Pasteur, Novartis, Pfizer, GSK, and Novavax, and TN has served on a data safety monitoring board for GSK (HPV vaccine, resigned in 2012) and GSK advisory boards (unpaid) for pertussis vaccine (2014 and 2016). SS has received funding for consultancy from CMAX Drug Studies Unit. All other authors: no conflicts.

The study centers were

Vaccine Trials Group, Princess Margaret Hospital; VIRTU staff of the Women’s and Children’s Hospital, Adelaide; VIRGo staff, University of Melbourne; National Centre for Immunisation Research & Surveillance of Vaccine Preventable Diseases, The Children’s Hospital of Westmead; AUSTRIALS; CMAX, Trialworks Clinical Research Services; Cairns Base Hospital; Auckland Clinical Studies Limited; Southern Clinical Trials Limited; RMC Medical Research Limited; Emeritus Research; SEALS, Prince of Wales Hospital; Department of Clinical & Biomedical Science, Geelong Hospital; Clinical Trials Unit, the Australian National University
Hospital; Hobart Sexual Health Service; Gold Coast Hospital; Youth Health Centre, Christchurch; Lung Institute of Western Australia.

Acknowledgments

We thank the trial participants, the staff of each trial centre, and the staff of CSL Limited who committed their time and effort to this study. We acknowledge Dr. Neil Formica for his helpful input into revising the manuscript and Dr. Jane Leong for coordinating the writing and review process and for reviewing the manuscript. We would also like to acknowledge Focus Diagnostics, Trident Clinical Research, Quintiles Inc, EMMES, Contact Management, Publicis Life Brands, and Medidata Solutions. The Melbourne WHO Collaborating Centre for Reference and Research on Influenza is supported by the Australian Government Department of Health and Ageing. HM acknowledges support from the NHMRC (CDF2 APP1084951).

References
